Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. BET bromodomain inhibitors, which have shown efficacy in several models of cancer, have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs. Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance.

[1]  A. Belkina,et al.  BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.

[2]  E. Winer,et al.  Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Bernards,et al.  Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.

[4]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[5]  Weiwei Shi,et al.  Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. , 2011, Cancer research.

[6]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[7]  K. Matsumoto,et al.  The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer , 2013, Oncogene.

[8]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[9]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[10]  William B. Smith,et al.  Genome-wide localization of small molecules , 2013, Nature Biotechnology.

[11]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[12]  Paul Ellis,et al.  Dissecting the heterogeneity of triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[14]  Carlos Caldas,et al.  Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. , 2013, Cell reports.

[15]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[16]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[17]  Jason J Burbank,et al.  Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. , 2014, The Journal of clinical investigation.

[18]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[19]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[20]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[21]  Shwu‐Yuan Wu,et al.  Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. , 2013, Molecular cell.

[22]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[23]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[24]  Gedge D. Rosson,et al.  Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. , 2013, Cell stem cell.

[25]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.

[26]  F. Rojo,et al.  PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects , 2015, Oncotarget.

[27]  Amber L. Couzens,et al.  The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.

[28]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[29]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[30]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[31]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[32]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[33]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[34]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[35]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[36]  Andrew L. Kung,et al.  NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. , 2014, Molecular cell.